.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EG04_Sirolimus.Sirolimus_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EG04_Sirolimus.Sirolimus_1| name: | Sirolimus_1 |
| ATC code: | L01EG04_1 | route: | oral |
| n-compartments | 1 |
Sirolimus, also known as rapamycin, is an immunosuppressant drug primarily used to prevent organ transplant rejection. It inhibits the mammalian target of rapamycin (mTOR), thereby suppressing T-cell proliferation and activation. Sirolimus is FDA-approved and is used in clinical practice, especially in renal transplantation.
Population PK in adult kidney transplant patients; results from model fitting to trough concentrations following multiple oral dosing.
Zhang, Y, et al., & Li, X (2021). Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study. Xenobiotica; the fate of foreign compounds in biological systems 51(12) 1408–1415. DOI:10.1080/00498254.2022.2025628 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34983304
Wang, D, et al., & Li, Z (2019). Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. Oncology letters 18(3) 2412–2419. DOI:10.3892/ol.2019.10562 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31452734
Li, S, et al., & Wang, Y (2022). Population Pharmacokinetic Analysis and Dosing Optimization of Sirolimus in Children With Tuberous Sclerosis Complex. Journal of clinical pharmacology 62(8) 948–959. DOI:10.1002/jcph.2033 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35094415